Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

NCT06557889 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

86

Enrollment

OTHER

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: Pembrolizumab + Cisplatin/Carboplatin + 5-FU

Sponsor

Institut Claudius Regaud